Gregg Vicky B 4

What Happened

• Vicky B. Gregg, a director of Quest Diagnostics (DGX), acquired 67 shares on January 28, 2026 at $183.51 per share, for a total of about $12,295. This was an acquisition (purchase) of company stock. The transaction was effected through a dividend reinvestment mechanism per the filing footnote.

Key Details

• Transaction date and price: 2026-01-28 at $183.51 per share.
• Shares acquired: 67; Total value: ~$12,295.
• Shares owned after transaction: Not disclosed in this Form 4.
• Footnote (F1): Shares were acquired under a dividend reinvestment plan administered by the reporting person's broker; such transactions are eligible for deferred reporting on Form 5 under Rule 16a-6, but the reporting person chose to report this on Form 4.
• Timeliness: Filing indicates code "L" (marked on the transaction); the filing also includes F1 noting the dividend reinvestment eligibility—retail investors should be aware this is a routine plan-based purchase, not an open-market timing decision.

Context

• Dividend reinvestment purchases are common and typically reflect automatic reinvestment of dividends rather than an active discretionary buy; they are generally considered routine rather than a strong bullish signal.
• The size of this purchase is small relative to typical director trades; there is no indication of option exercise, gift, or sale in this filing.